Portfolio Lab

Tema Heart & Health ETF

  • ETF
  • Ticker HRTS
  • NASDAQ

Performance, volatility and drawdowns of Tema Heart & Health ETF since 11/2023, with distributions reinvested and calculated in US dollars. As of 20 Nov 2026.

Performance

HRTSGlobal equities (VT)

$10,000 grew to $14,215. Global equities (VT): $15,356.

Distributions reinvested, before taxes and brokerage costs. Dashed: Global equities (VT) for comparison.

Declines from the peak

Lowest point −25.8% in 04/2025, measured from the peak in 07/2024. It took 16 months to get back to the old peak.

Annual returns

Best year 2025 at +23.9%, weakest 2024 at −4.3%. 1 of 2 full years were positive. * partial year.

Similar ETFs

Frequently asked questions

How has HRTS performed since 11/2023?

$10,000 grew to $14,215 by 20 Nov 2026, which is +12.4% per year. Distributions are reinvested; taxes and brokerage costs are not deducted.

How volatile is HRTS?

Volatility was 17.9% per year, measured on monthly returns. The largest decline from a peak was −25.8%, with the low in 04/2025.

How does HRTS compare with a broad equity ETF?

Over the same period Global equities (VT) returned +15.4% per year at 12.2% volatility, HRTS returned +12.4% at 17.9%. The correlation of monthly returns was 0.48; 1 would mean they moved in lockstep.

What does HRTS hold?

HRTS holds 45 positions. The largest are Eli Lilly & Co, Thermo Fisher Scientific Inc and UnitedHealth Group Inc; the 10 largest together make up 48.4% of the fund (holdings as of 31 Aug 2026, according to the fund's filing with the SEC).

Which currency are the figures in?

In US dollars, the currency of the US listing.

Reference data of securities: source ESMA (FIRDS reference data) and SEC (EDGAR).

Not investment advice: results in Portfolio Lab are model calculations based on historical data and your inputs. Past performance is not a reliable indicator of future results.

Tema Heart & Health ETF (HRTS): Return and risk